- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | HHS abandons mRNA vaccine research | ||
| 18:46 | Novo pushes back against obesity drug compounders as competition intensifies | ||
| 17:46 | Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share | ||
| Di | Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO | ||
| Di | Trump threatens up to 250% tariffs on pharma imports | ||
| Di | David Altshuler, geneticist who helped transform Vertex, to retire next year | ||
| Di | Vertex plan to build on pain drug breakthrough hits hurdles | ||
| Mo | Gates Foundation pledges $2.5B toward women's health research | ||
| Mo | Drugmakers score policy win in fight against 340B | ||
| Mo | A brain biotech slumps even with 'best case' seizure data | ||
| Mo | Xoma strikes deals to buy struggling biotechs HilleVax, Lava | ||
| Mo | The race to scale to 1,000 liters and beyond in gene therapy manufacturing | ||
| Fr | Regeneron cancer bispecific rejected again; Allogene discloses trial death | ||
| Fr | Trump redoubles threats in attempt to strongarm drugmakers on prices | ||
| Fr | Experts ousted from CDC panel warn of damage to US vaccine policy | ||
| Do | In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A | ||
| Do | Alnylam reaches new highs on strong sales of closely watched rare disease drug | ||
| Do | Venture firm Frazier closes $1.3B fund for early-stage biotech investing | ||
| Do | Moderna to lay of 10% of workforce in 'difficult but necessary step' | ||
| Do | Lilly's Mounjaro protects heart health in large diabetic study | ||
| 30.07. | Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval | ||
| 30.07. | Vinay Prasad's ouster leaves biotech guessing at FDA direction | ||
| 30.07. | J&J tests direct CAR-T marketing with first Carvykti ad | ||
| 29.07. | Merck plans spending shift to boost business beyond Keytruda | ||
| 29.07. | Novo cuts guidance, names new CEO as obesity drug challenges mount |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .